@kayleenicole._'s Wegovy journey: what to know

What did @kayleenicole._ actually say?

This is a first-injection video. The creator says she let the pen sit out for about 30 minutes before using it, cleaned the injection site with an alcohol prep pad, and chose the abdomen area because she'd heard good things about it. She also mentions removing a bubble from the pen before injecting. There are no wild medical claims here. It's a personal journey post, not a tutorial. Still, first-injection content reaches real people who are starting the same drug, so the details matter.

What she described is fairly standard: temperature tempering, alcohol swabbing, abdominal injection site. The bubble comment is worth examining. So is the 30-minute wait time and whether her site selection choice holds up.

Does the science back this up?

Mostly yes, with one notable nuance on the bubble question. Letting a prefilled injector pen reach closer to room temperature before use is a commonly recommended practice to reduce injection site discomfort. Novo Nordisk's own prescribing information for Wegovy advises storing it in the refrigerator and allowing it to come to room temperature before use, though the official guidance specifies up to 28 days at room temperature after first removal.

On injection site selection, the abdomen is one of three approved injection sites for semaglutide, along with the thigh and upper arm. A 2022 pharmacokinetics analysis (Kapitza et al., Diabetes, Obesity and Metabolism) found no clinically significant difference in semaglutide absorption across sites, though the abdomen and thigh showed slightly more consistent absorption than the upper arm in some subgroup analyses. So her preference for the abdomen is reasonable, even if it's not definitively superior.

The bubble concern is trickier. Wegovy is a prefilled auto-injector pen, not a syringe. For auto-injector pens, small air bubbles are generally not a concern, because the mechanism delivers the dose automatically and bubbles in a subcutaneous injection do not carry the same risk as in an intravenous one. Trying to remove bubbles from an auto-injector pen is a step that applies to traditional syringes, not this device format.

What did they get wrong (or right)?

The bubble removal concern is likely a carryover habit from syringe-based injection training, or something she read that applies to a different device type. Wegovy's FlexTouch pen is an auto-injector, and Novo Nordisk's instructions do not include a step for removing air bubbles. Attempting to manipulate the pen to address a bubble could interfere with the dose delivery mechanism if done incorrectly. That's not a catastrophic error, but it's worth correcting for anyone following along.

What she got right: alcohol swabbing the site before injection is consistent with standard practice, though research on this is more mixed than most people realize. A 2014 Cochrane-adjacent review noted that skin antisepsis before subcutaneous injection has limited evidence supporting it as strictly necessary, but it is the standard of care and a reasonable precaution. Waiting for the pen to warm up is also genuinely useful for comfort. Her injection site choice is clinically fine.

• Bubble removal: not applicable to auto-injector pens, likely a misapplied concept
• 30-minute warm-up: reasonable and consistent with general guidance
• Abdominal site: clinically appropriate, supported by pharmacokinetic data
• Alcohol swab: standard practice, though evidence base is softer than commonly assumed

What should you actually know?

If you're starting Wegovy, the injection itself is genuinely not complicated, but small technique errors can affect comfort and potentially dose delivery. Here are the things that actually matter, based on the prescribing information and clinical guidance.

First, Wegovy is a subcutaneous auto-injector pen. You do not need to draw out air or manipulate the pen the way you would a syringe. The dose is pre-loaded. Follow the manufacturer's instructions for your specific pen, not general injection advice meant for syringes or vials.

Second, rotate injection sites between doses. Using the same spot repeatedly increases the risk of lipohypertrophy, a buildup of fatty tissue under the skin that can impair drug absorption. The abdomen, thigh, and upper arm are all approved sites.

Third, Wegovy is a titration-based medication. The starting dose is not the maintenance dose. The dose escalation schedule exists to reduce gastrointestinal side effects, which are the most common reason people discontinue. Nausea, vomiting, and diarrhea are reported in a significant share of trial participants, per the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine).

Finally, this video includes PCOS and postpartum hashtags. Both populations have specific clinical considerations with GLP-1 use. If you are postpartum and breastfeeding, semaglutide is not recommended due to lack of safety data in that population. Talk to your prescriber before starting.